PORTFOLIO NEWS Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development December 11, 2023 Read More » Plexium Initiates Dosing in Phase 1 Study of PLX-4545, a Potent and Selective Degrader of the Transcription Factor IKZF2 December 11, 2023 Read More » Carmot Therapeutics Enters into Definitive Merger Agreement with Roche December 4, 2023 Read More » Neurona Therapeutics Presents New Clinical Data from First Cohort in Ongoing Phase I/II Open-Label Trial of NRTX-1001 Cell Therapy for Drug-resistant Mesial Temporal Lobe Epilepsy (MTLE) December 1, 2023 Read More » Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, A First-in-Class Oral MRGPRX2 Antagonist, In Atopic Dermatitis November 28, 2023 Read More » RAPT Therapeutics Announces Publication of Phase 1A/1B Clinical Trial of Zelnecirnon (RPT193) To Treat Atopic Dermatitis In Allergy November 27, 2023 Read More » Carmot Therapeutics Commenced Phase 2 Clinical Trial of Novel Dual GLP-1/GIP Receptor Agonist CT-868 for the Treatment of Type 1 Diabetes November 15, 2023 Read More » RAPT Therapeutics Reports Third Quarter 2023 Financial Results November 13, 2023 Read More » NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting® November 13, 2023 Read More » Kallyope and Sosei Heptares Nominate First GPCR Target for Therapeutic Development in Gastrointestinal Diseases November 10, 2023 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development December 11, 2023 Read More »
Plexium Initiates Dosing in Phase 1 Study of PLX-4545, a Potent and Selective Degrader of the Transcription Factor IKZF2 December 11, 2023 Read More »
Neurona Therapeutics Presents New Clinical Data from First Cohort in Ongoing Phase I/II Open-Label Trial of NRTX-1001 Cell Therapy for Drug-resistant Mesial Temporal Lobe Epilepsy (MTLE) December 1, 2023 Read More »
Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, A First-in-Class Oral MRGPRX2 Antagonist, In Atopic Dermatitis November 28, 2023 Read More »
RAPT Therapeutics Announces Publication of Phase 1A/1B Clinical Trial of Zelnecirnon (RPT193) To Treat Atopic Dermatitis In Allergy November 27, 2023 Read More »
Carmot Therapeutics Commenced Phase 2 Clinical Trial of Novel Dual GLP-1/GIP Receptor Agonist CT-868 for the Treatment of Type 1 Diabetes November 15, 2023 Read More »
NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting® November 13, 2023 Read More »
Kallyope and Sosei Heptares Nominate First GPCR Target for Therapeutic Development in Gastrointestinal Diseases November 10, 2023 Read More »
